Faculty Information |
|
Language | English |
The announcement title | S-1/oxaliplatin (SOX) plus bevacizumab (Bev) as first line followed by S-1/irinotecan (IRIS) plus cetuximab (Cmab) as second line therapy in metastatic colorectal cancer (mCRC)(SOBIC trial). |
Academic Society name | ESMO Asia 2017 Congress |
Conference Type | International Society |
Announcement form | Poster presentation |
Presentation Type | General Lecture |
Lecture Type | Poster Display session |
Publisher and common publisher | Nakamoto Yoshihiko, Mikami R, Umeki M, Tokugawa Y, Okumoto T, Kawamura T, Fujiwara H, Doi S, Noda Masafumi, Tomita Naohiro |
Date | 2017/11/18 |
Venue (city and name of the country) |
Suntec City |